R&D Towards better quality of life, GNT Pharma

Pipeline

Global New Drug Development Pipeline

Overview

Crisdesalazine is a multi-target drug that removes both free radicals and inflammation, which are proven contributors to Alzheimer’s disease and other neurodegenerative brain diseases.
Pharmacological action: (1) next-generation anti-inflammatory effect through inhibition of mPGES-1; (2) Remove free radicals (antioxidant)
Safety and anti-inflammatory effects are substantially improved with few adverse drug effects compared to nonsteroidal anti-inflammatory drugs (NSAIDs).
Demonstration of efficacy in animal models of neurodegenerative diseases.
Significant inhibition of ATN (A: Amyloidopathy, T: Tauopathy, N: Neurodegeneration), important pathological and diagnostic markers of AD in cultured cells and mouse models of dementia.
Demonstration of improvement in cognitive function in pet dogs with canine cognitive dysfunction syndrome, a canine disease with strong clinical and pathological parallels to human Alzheimer’s disease.

Indications

Comparison of Crisdesalazine and current drugs for Alzheimer’s Disease patients

		Crisdesalazine (AAD-2004)	Investigational Drugs	donepezil	memantine
Mode of Action		mPGES-1 inhibition1+spin trapping anti-oxidant	Anti-oxidant NSAIDs Anti-Beta amyloid drugs	acetylcholine esterase inhibition	NMDA receptor antagonist
Efficacy In AD Models	APP/PS1 mouse	Improves cognition at early to severe stage Reduces beta amyloid Prevents BBB damage	Improves cognition Reduces beta amyloid	Improves cognition Reduces beta amyloid	Improves cognition Reduces beta amyloid
	betaCTF99 mouse2,3	Prevents neuronal death Prevents neuritic atrophy	ND (Not Determined)	ND	ND
	GiDs mouse4	Prevents reactive astrocytes Prevents neuronal death Improves cognitive function
	3D AD Cell Cultures4	Prevents reactive astrocytes Prevents neuronal death Prevents tauopathy
CCDS (Similar to Alzheimer’s disease)		Improves cognitive function Slows disease progression	ND	Improves cognition	ND
Drug Development Stage		Approved for CCDS (Feb 2021)	FDA Approved-Amyloid β antibodies as a New Drug: Aducanumab (conditional, 2024), Lecanemab (2023), Donanemab (2024)	Approved for AD (1996)	Approved for AD (2003)

Related Articles